peptide0 listings

CagriSema

CagriSema (Cagrilintide + Semaglutide)

Fixed combination of cagrilintide (amylin) and semaglutide (GLP-1). Weight research.

Weight researchMetabolic research

/ research index

The research base

Research Maturity

★★★★☆

4/5 — Volume of studies

Evidence Strength

★★★★☆

4/5 — Quality of evidence

Co-formulated amylin analog and GLP-1 agonist showing additive weight reduction beyond either component alone.

/ mechanism of action

How it works

Combines amylin receptor agonism (cagrilintide) with GLP-1 agonism (semaglutide) for complementary appetite and satiety pathways.

/ research dosing

Common research protocols

Range

Cagrilintide 2.4mg + Semaglutide 2.4mg/week (target dose)

Frequency

Once weekly subcutaneous

Route

Subcutaneous

Cycle

Titrate both components over weeks

Research notes

Each component titrated in parallel. The amylin + GLP-1 combination produced greater weight reduction than semaglutide alone in trials. Note this is research into the combination ratio.

References

PMID: 37923569 →ClinicalTrials.gov NCT05394519

FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.

/ standalone use

As a solo compound

Standalone combination product. Titration required for both components.

/ side effects

What to know

GI effects from the GLP-1 component dominate; dose-dependent.

/ timeline

Realistic expectations

Effects build over months

FOR RESEARCH USE ONLY. CagriSema is intended for laboratory research and not for human consumption.